Our Pipeline
Clinical Status of PNB-281
Peptinovo’s initial candidate, PNB-281 (PALM™ with paclitaxel), is currently approved for clinical testing in Australia. The FDA has approved the toxicity testing results and IND submission is underway. Certified GMP manufacturing is complete and product available for patient enrollment. Toxicology studies are published and demonstrate superior safety profile.
The Peptinovo team has developed four other leading chemotherapy drugs (TOP1/ exatecan, Tubulin
Disruptors, Platinum Drugs and Gemcitabine) leveraging the PALM™ Technology Platform.
Our goal is to begin first-in-human testing in the near future.
Robust Future Pipeline
The platform continues to build.
On the pharmacology side, we have now demonstrated in vitro efficacy in several cell lines using one chemotherapy drug, Paclitaxel.
Additionally, we have demonstrated the ability of our nanoparticle technology to carry several other chemotherapy drugs (Tubulin Disruptors, Platinum drugs and Gemcitabine) and suppress cancer cell growth.